Risk-based Monitoring Software Market by End User (Pharma & Biopharmaceutical Co., Medical Device Co., CROs), Delivery Mode (Web Hosted, On-premise, Cloud-based), Type (Enterprise, Site), Component (Software, Services) – Global Forecast to 2025

2020-05-19
Price :
Published : May-2020
No. of Pages : 137

“Risk-based monitoring (RBM) software market is projected to grow at a CAGR of 13.3%.”

The RBM software market is expected to reach USD 511 million by 2025 from USD 273 million in 2020, at a CAGR of 13.3% during the forecast period. The RBM software market has witnessed various advancements in products and their approvals to meet the needs of the pharmaceutical research and development industry worldwide.

Growth in the market can primarily be attributed to factors such as the cost and time efficiency of RBM solutions, rising number of clinical trials, and increasing government funding and grants to support clinical trials

“The Enterprise RBM Software segment to hold the largest market share in 2020.”

Based on type, the RBM software market is segmented into Enterprise RBM Software and Site RBM Software. In 2020, the Enterprise RBM Software segment is expected to command the largest share of the RBM software market. The large share of this segment can be attributed to the widespread adoption of enterprise RBM software by end-users as it allows all authorized professionals to have access to clinical trial data and metrics placed at a centralized location.

“The software component segment to hold the largest market share in 2020.”

Based on the component, the RBM software market is segmented into Software and Services. In 2020, the software segment is expected to command the largest share of the RBM software market. The large share of this segment can be attributed to the increasing R&D expenditure in the life science and clinical research industries, increasing number of clinical trials, and rising customer base

 “The pharmaceutical and biopharmaceutical companies segment to hold the largest market share in 2020.”

Based on end-user, the RBM software market is segmented into pharmaceutical and biopharmaceutical companies, CROs, medical device companies, and other end users. In 2020, the pharmaceutical and biopharmaceutical companies segment is expected to command the largest share of the RBM software market. The increasing R&D expenditure of pharmaceutical and biopharmaceutical companies is the major factor driving the growth of this end-user segment.

 “The Asia Pacific region to witness the highest growth during the forecast period.”

Geographically, North America dominated the global RBM software market in 2020. However, the Asia Pacific market is expected to register the highest during the forecast period. The major factors driving the growth of the Asia Pacific market include increasing government funding to support clinical trials, the presence of less stringent regulatory guidelines as compared to developed nations, a large patient base, low operating costs for conducting clinical trials, shortage of trial volunteers in Europe and North America, and the growing number of pharmaceutical companies and CROs in the region.

Break of primary participants was as mentioned below:

  • By Company Type: Tier I: 55%, Tier II: 25%, Tier III: 20%
  • By Designation:C-Level Executives: 35%, Directors: 25%, Others: 40%
  • By Region:North America: 20%, Europe: 25%, Asia Pacific : 40%, RoW: 15%

Oracle (US), Medidata Solutions (US), and Parexel International Corporation (US) were the leading players in the RBM software market.

Research Coverage

This report studies the RBM software market based on type, component, delivery mode, end-user, and region. The report also studies the different factors (such as drivers, restraints, challenges, and opportunities) affecting the market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to four main regions and respective countries.

Key Benefits of Buying the Report

This report focuses on various levels of analysis—industry trends, market shares of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the RBM software market, and their drivers, restraints, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the RBM software and garner greater market shares.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : marketsandmarkets
More Reports
Title Price Buy Now

Immunotherapy Drugs Market by Type (Monoclonal Antibodies, Check Point Inhibitors, Interferons, and Interleukins), Therapy Area (Cancer, Autoimmune diseases& Inflammatory, Infectious Diseases), End User (Hospitals, Clinics ) – Global Forecast to 2025

 “The immunotherapy drugs market is projected to grow at a CAGR of 11.0% during the forecast period (2020–2025).” The global immunotherapy drugs market is projected to reach USD 274.6 billion by 2025 from USD 163.0 billion in 2020, at a CAGR of 11.0 % during the forecast period. Market growth is primarily driven by the rising demand for immunotherapies over conventional treatments and a growing prevalence of target indications. However, timeline issues, side-effects, and manufacturing complexities are expected to restrict market growth to a certain extent. “Monoclonal antibodies are expected to witness high demand during the forecast period.” The adoption of immunotherapy in cancer has been rising in recent years due to the introduction of safe and efficient treatments.......
$4950

Ambulatory Surgical Centers Market by Product (EHR, Practice Management, Telehealth, Healthcare Analytics, PHM, Supply Chain Management, RCM, Surgical planning, Quality Management), Specialty Type (Single, Multi-specialty) – Global Forecast to 2025

The Ambulatory Surgical Centers market is projected to reach USD 7.2 billion by 2025 from 2.1 billion in 2020 at a CAGR of 27.6% during the forecast period.There is a growing inclination across the globe towards the adoption of healthcare IT technologies due to the increasing need to deliver quality care to patients while curtailing escalating healthcare costs. These robust IT solutions are designed to streamline workflow in healthcare systems, reduce expenses, and facilitate compliance with stringent regulatory guidelines. By-products and services, the healthcare providers segment accounted for the largest share of the Ambulatory Surgical Centers market in 2018 Based on products and services, the Ambulatory Surgical Centers market is segmented into healthcare provider solutions, h......
$5650

Veterinary Vaccines Market by Disease (Swine Pneumonia, Avian Influenza, Rabies, Coccidiosis, Brucellosis, Canine Distemper), Type (Poultry, Livestock, Aquaculture, Porcine, Canine), Technology (Inactivated, Toxoid, Recombinant) – Global Forecast to 2025

“The veterinary vaccines market is projected to grow at a CAGR of 7.2% during the forecast period (2020–2025).” The global veterinary vaccines market size is projected to reach USD 11.3 billion by 2025 from USD 8.0 billion in 2020, at a CAGR of 7.2%. The growth of this market is driven majorly by factors such as the initiatives by various government agencies and animal associations to maintain animal health, rising incidence of zoonotic diseases, growth in the companion animal population, and the rising demand for animal-derived food products are driving the growth of this market. On the other hand, the high storage cost of vaccines is restraining market growth. “By technology, the recombinant vaccines segment is expected to grow at the highest CAGR during the forecast period......
$4950

COVID-19 Impact on Vaccines & Drugs Market – Global Forecast to 2025

"The global COVID 19 vaccines market is projected to grow at a CAGR of -14.9% during the forecast period." The global COVID-19 vaccines market is projected to reach USD 1,401 million by 2025 from USD 2,273 million in 2022, at a CAGR of -14.9% during the forecast period. The growth of the global COVID-19 vaccines market is majorly attributed to the increasing number of people infected with COVID-19 and growing funding for vaccine development. "The global COVID 19 drugs market is projected to grow at a CAGR of -57.8% during the forecast period." The global COVID-19 drugs market is projected to reach USD 2 million by 2025 from USD 165 million in 2020, at a CAGR of -57.8% during the forecast period. The growth of COVID-19 drugs market is attributed primarily to use of repurposed drugs......
$5650

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2020. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides ......
$1000

Coronavirus Disease 2019 (COVID-19) Sector Forecast: Analyst Consensus Sales Forecast

Coronavirus Disease 2019 (COVID-19) Sector Forecast: Analyst Consensus Sales Forecast Summary This report contains a summary of the analyst consensus forecasts available in the GlobalData Pharma Intelligence Center Drug Sales and Analyst Consensus Database for the Indication COVID-19. Despite the rapid development of COVID-19 therapies being developed the majority of the COVID-19 pipeline is in early stage development so there are few forecasts available. Currently there are three drugs indicated for COVID-19 which have analyst consensus forecasts available. Scope This 27-page report gives important, expert insight you won't find in any other source. 7 figures throughout the report illustrate major points and trends in COVID sales forecasts and company pipelines. This report is require......
$495

Medical Marijuana: Consumers’ Perspectives in the US and UK

Medical Marijuana: Consumers' Perspectives in the US and UK Summary GlobalData's Medical Marijuana, Consumers' Perspectives report combines an extensive survey and analysis of patients' perspectives in the US and UK to provide an in-depth consumer-centered review of the medical marijuana market. Components of the report include an in-depth breakdown of the survey and its respondents, detailed analysis of consumers' concerns and opinions of medical and recreational marijuana, information from interviews with patients receiving treatment with medical marijuana in the US and UK, and an assessment of the impact of the COVID-19 pandemic on the medical marijuana space. The report evaluates trends across different age groups, health statuses, and other parameters to inform insightful compariso......
$7995

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Russia

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Russia Summary GlobalData, the industry analysis specialist, has released its latest report: "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Russia". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Russia. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by Glo......
$1995

Pharmaceutical Trade and Supply Chain Survey – Q1 2020: Coronavirus Disease 2019 (COVID-19) Sector Impact

Pharmaceutical Trade and Supply Chain Survey - Q1 2020: Coronavirus Disease 2019 (COVID-19) Sector Impact Summary GlobalData's Coronavirus Disease 2019 (COVID-19) Sector Impact: Pharmaceutical Trade and Supply Chain Survey - Q1 2020 provides in-house analyst expertise on the results of a 5 minute survey of 136 GlobalData Pharma clients and prospects, which was fielded from March 13, 2020 to March 24, 2020. Scope - This report provides an assessment of how the pharmaceutical industry perceives the supply chain disruption caused by the COVID-19 pandemic, including the challenges associated with clinical trials, logistics, API and finished dose manufacturing. - Since the first case was diagnosed in Wuhan, China, in December 2019, COVID-19 cases have continued to rise rapidly across the gl......
$1495

Social Media: Coronavirus Disease (COVID-19) Sector Impact

Social Media: Coronavirus Disease (COVID-19) Sector Impact Summary The highly contagious coronavirus (SARS-CoV-2), dubbed COVID-19 (formerly 2019-nCoV), which emerged at the close of 2019, has led to a medical emergency across the world, with the World Health Organization (WHO) officially declaring the novel coronavirus a pandemic on March 11, 2020. This report analyzes GlobalData's social media Influencer dashboards to understand Influencer trends since the pandemic began and what key Influencers are discussing online about COVID-19. across the world, with the World Health Organization (WHO) officially declaring the novel coronavirus a pandemic on March 11, 2020. Scope - This report analyzes Influencer trends since the pandemic began and what assesses what key Influencers are discussi......
$995
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy